Dynamic profile of differentiated thyroid cancer in male and female patients with thyroidectomy during 2000–2013 in China: a retrospective study

Hui-xian Yan¹,², Ping Pang³, Fu-lin Wang⁴, Wen Tian⁵, Yu-kun Luo⁶, Wei Huang⁷, Guo-qing Yang¹, Nan Jin¹, Li Zang¹, Jin Du¹, Jian-ming Ba¹, Jing-tao Dou¹, Yi-ming Mu¹ & Zhao-hui Lyu¹

The study aimed to investigate the gender-related differences of disease onset, age distribution, blood type, clinical characteristics, and malignant behaviors of differentiated thyroid carcinoma (DTC) in Chinese patients. A total of 7385 consecutive thyroid cancer patients who underwent thyroidectomy were retrospectively reviewed. 4087 (55.3%) were diagnosed as benign and the other (3298, 44.7%) were as malignant. DTC accounted for 97.6% in the malignant tumor. More single nodules turned out to be DTC in male compared to multiple nodules (46.9% vs. 40.4%, P = 0.004). The proportion increased along with the increase of year during 2000–2013, which was from 7.5% to 68.1% in males and from 16.2% to 66.7% in females. The level of preoperative TSH was significantly higher in patients with DTC compared to the patients with benign (1.97 vs. 1.57 mIU/L, P < 0.001). The proportion of thyroid cancer was dominated in blood type B and the lowest incidence in blood type A in male, the difference was not statistically significant. The results showed that age, nodule number, BMI and serum TSH were the related factors for DTC. More aggressive behaviors of DTC were observed in male patients, and more attention should be focused on the timely diagnosis and treatment of these patients.

Thyroid cancer is a rare malignancy that occurs more frequently in female. The incidence of thyroid cancer has been steadily rising worldwide in recent years. In the United States, the estimated overall incidence of thyroid cancer has been increased by 6.6% annually from 2000 to 2009, ranking the first among all cancers. According to the surveillance of Epidemiology and End Results program, the age-adjusted incidence rate of thyroid cancer has been reported to be about 13.5 per 100,000 people in 2015. The high variability (up to nearly tenfold) in the thyroid cancer incidence was explained by genetic factors, environmental influences, and access to medical care, geographic area and ethnicity.

Differentiated thyroid carcinoma (DTC) is the most common type of thyroid cancer, accounting for as high as 90% of all patients. It originated from thyroid follicular epithelial cells, and mainly includes papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), and a minority of Hurthle cell carcinoma or eosinophilic cell carcinoma. More and more studies have been focused on DTC, but the gender related characteristics of the disease have not been well established. Moreover, the ABO blood type, as a marker of familial and genetic factors, has been reported to associate with the risk of several malignancies, including gastric, epithelial ovarian and pancreatic cancer. However, few studies have been focused on the possible association between ABO blood type and the risk of thyroid cancers in Chinese patients.

¹Department of Endocrinology, Chinese PLA General Hospital, Beijing, 100853, China. ²Beijing Haidian Hospital, Beijing Haidian Section of Peking University Third Hospital, Beijing, 100080, China. ³Department of Endocrinology, Hainan Branch of PLA General Hospital, Sanya, 572013, Hainan, China. ⁴Department of Pathology, Chinese PLA General Hospital, Beijing, 100853, China. ⁵Department of General Surgery, Chinese PLA General Hospital, Beijing, 100853, China. ⁶Department of Ultrasonography, Chinese PLA General Hospital, Beijing, 100853, China. Hui-xian Yan and Pang Ping contributed equally to this work. Correspondence and requests for materials should be addressed to Z.-h.L. (email: metabolism301@126.com)
Therefore, the study aimed to investigate the gender-related differences of disease onset, age distribution, blood type, clinical characteristics, and malignant behaviors of DTC in Chinese patients.

Material and Methods

Patients. This study was approved by the Ethical Committee of the institutional review board of the People Liberation Army General Hospital (Beijing, China) and written informed consent was obtained from all patients. All methods were performed in accordance with the relevant guidelines and regulations.

A total of 7,385 consecutive thyroid cancer patients who underwent thyroidectomy at the Department of General Surgery, PLA General Hospital during January 2000 to January 2013 were retrospectively reviewed. All patients who were diagnosed with thyroid cancer were pathologically confirmed and had complete medical records. The physical examination and laboratory tests were performed. Fine needle aspiration biopsy (FNAB) test was performed only in patients with suspicious US features.

Surgical indications were more than one thyroid nodule confirmed by ultrasound with suspicious US features: 1) Micro calcifications, infiltrative margins, anteroposterior/transversal (AP/TR) diameters ≥1, solitary, and hypoechoic, large goiter with findings suggestive of malignancy or indeterminate/suspicious FNAC finding; 2) With clinical symptoms of hoarseness, dysphagia and compression symptoms associated with nodules; 3) No contraindications for surgical procedure; 4) The informed consent of the patients for surgery.

Laboratory data were obtained from all patients, including thyroid profiles, ABO blood type, and thyroid ultrasonography. The basic information and medical histories of the patients were collected by professional doctors.

Laboratory tests. Preoperative blood tests were performed one day to one week prior to thyroidectomy with the patients in a fasting state. Laboratory data available were ABO blood type and thyroid profile, consisting of serum Thyroid Stimulating Hormone (TSH), thyroid peroxidase antibody (TPO-Ab) and thyroglobulin antibody (TG-Ab). Laboratory data were measured with the same automated immune chemiluminescent assay (ICMA, Abbott, Abbott Park, IL, USA) at the laboratory of our hospital. The sensitivity of TSH assay was 0.01 mIU/L. Serum TPO-Ab of >60 U/L and/or TG-Ab of >60 U/L were considered as high serum autoantibody values.

Thyroid ultrasonography was performed using a 5- to 17-MHz linear array transducer (LOGIQ 9, GE Healthcare, Milwaukee, WI, or iU22, Philips Medical Systems, Bothell, WA). The images were reviewed at the Picture Archiving and Communication System (PACS, GE Medical System, Milwaukee, WI, USA) by two experienced nuclear medicine physicians that blinded to the original diagnosis of the disease. Data of thyroid nodule size, number, echo pattern characteristics, calcification and blood flow were recorded.

Pathology. The postoperative histological results were available for the entire cohort of the patients. The results were reviewed by an experienced pathologist to confirm the histology of the primary lesion (benign or malignant nodules) and the pathological types of malignant nodules. In patients with multifocal thyroid cancer, the largest tumor diameters of the nodules were reported. Status of extra thyroidal invasion, lymph node metastasis, and distant metastasis were recorded and the tumors were staged according to the staging system of the American Joint Committee on Cancer.

Statistical analysis. Body mass index (BMI) was calculated by the weight (kg) divided by the square of height (m). Obesity was defined as BMI ≥ 28 kg/m² and overweight was defined as BMI 24 kg/m² and BMI < 28 kg/m² recommended by the Working Group on Obesity in China. Serum TSH values were classified as follows: ≤ 0.3 mIU/L, 0.3–1.0 mIU/L, 1.0–1.9 mIU/L, 1.9–4.8 mIU/L and > 4.8 mIU/L, based on cutoff values predetermined in a previous population study. Categorical data were presented as count and percentage. Continuous variables were presented as mean and standard deviation (SD), or median with the interquartile range (IQR) due to their non-normal distributions. For continuous data, differences between females and males were compared using the nonparametric Mann-Whitney test. Frequency distributions were compared with the χ² test. Multiple logistic regression model was used to evaluate the related factor. All statistical analysis were two-sided and considered significant when p < 0.05. Statistical analyses were performed using the statistics software, SPSS 19.0 (SPSS Inc., Chicago, IL, USA).

Statement of Ethics. The appropriate ethics review board approved the study design.

Results

Characteristics of patients. In total 7,385 patients were recruited in the study, which consisted of 5,246 (71.0%) females and 2,139 (29.0%) males. The mean ± SD age of the patients was 47 ± 12 years in females and 48 ± 13 years in males, respectively. Among them, 4,087 (55.3%) were diagnosed as benign and the other (3,298, 44.7%) were as malignant. DTC accounted for 97.6% (3,218/3,298) in the malignant tumor. 80 patients were non-DTC follicular-type papillary carcinoma nodules (1.1%), which were further consisted of 37 medullary carcinoma nodules, 34 follicular carcinoma nodules, 14 anaplastic carcinoma nodules, 7 malignant lymphoma nodules, 1 metastatic carcinoma, and 21 Hürthle cell adenomas (HCA).

The patients with benign tumor had an older age, larger nodule size and lower TSH level than those with DTC whether in male or in female (all P < 0.05) in Table 1. More single nodules turned out to be DTC in male compared to multiple nodules (46.9% vs. 40.4%, P = 0.004). While no significantly difference in female was observed (44.4 vs. 44.4%, P = 0.922).

The peak of DTC proportion in thyroid nodules was at the group of 30–39 years in female and of younger than 30 years in male among the patients with thyroidectomy. And then the proportion of DTC decreased along with the increase of age (Fig. 1). Compared with the characteristics of male and female thyroid cancer patients, we found that there were significant differences in nodule size, BMI, nodular type and TSH between the two groups.
Table 1. The characteristics of patients diagnosed as benign or DTC in the study. Note: TSH levels are presented as median (interquartile range); DTC, differentiated thyroid cancer; *there were 2423 patients with solitary and 4846 with multiple.

| Factor                     | Total (3218) | Benign (4087) | P  | Male (908) | Benign (1200) | P  | Female (2310) | Benign (2887) | P  |
|----------------------------|--------------|---------------|----|------------|---------------|----|--------------|---------------|----|
| Age, mean ± SD, years      | 44 ± 12      | 49 ± 12       | <0.001 | 44 ± 12 | 52 ± 12       | <0.001 | 44 ± 11      | 48 ± 12       | <0.001 |
| Nodule size, mean ± SD, cm | 1.4 ± 1.2    | 3.0 ± 1.7     | <0.001 | 1.5 ± 1.2 | 3.2 ± 1.8     | <0.001 | 1.3 ± 1.1    | 2.9 ± 1.7     | <0.001 |
| Body mass index, kg/m²     | 24.6 ± 3.5   | 24.5 ± 3.4    | 0.146 | 26.4 ± 3.4 | 25.6 ± 3.1    | <0.001 | 23.9 ± 3.3   | 24.0 ± 3.4    | 0.275 |
| Nodule type*               |              |               | 0.124 |            |               | 0.004 |              |               | 0.922 |
| Single (2423)              | 1095         | 1328          |      | 369        | 418           |      | 726          | 910           |    |
| Multiple (4846)            | 2098         | 2748          |      | 529        | 780           |      | 1569         | 1968          |    |
| TSH, median (IQR), mIU/l   | 1.97(1.21–3.05)| 1.57(0.89–2.55)| <0.001 | 1.66(1.03–2.56)| 1.44(0.9–2.19) | 0.001 | 2.08(1.30–2.36)| 1.62(0.89–2.76)| <0.001 |

Table 2. Comparison of characteristics of thyroid cancer in men and women. Note: TSH levels are presented as median (interquartile range); DTC, differentiated thyroid cancer; *there were 1095 patients with solitary and 2098 with multiple.

| Factor                     | Male          | Female        | P value |
|----------------------------|---------------|---------------|---------|
| Age, mean ± SD, years      | 44 ± 12       | 44 ± 11       | 0.669   |
| Nodule size, mean ± SD, cm | 1.5 ± 1.2     | 1.3 ± 1.1     | <0.001  |
| Body mass index, kg/m²     | 26.4 ± 3.4    | 23.9 ± 3.3    | <0.001  |
| Nodule type*               |               |               | <0.001  |
| Single (1095)              | 369(41.1%)    | 726(31.6%)    |         |
| Multiple (2098)            | 529(58.9%)    | 1569(68.4%)   |         |
| TSH, median (IQR), mIU/l   | 1.66(1.03–2.56)| 2.08(1.30–3.26)| <0.001  |

Figure 1. The distribution of differentiated thyroid cancers in different age groups.

(Table 2, all P < 0.001). The nodule size and BMI of the male group were significantly higher than those of the female group (1.5 vs. 1.3; 26.4 vs. 23.9). For the composition of the nodular type, the proportion of single in the male group accounted for 41.1%, while the female group was 31.6% (P < 0.001). The median TSH in the male group was 1.66, which was significantly lower than that in the female group (2.08).

**Years.** As shown in Fig. 2A, the proportion of DTC increased during in the patients with thyroidectomies both in males and in females. The proportion increased along with the increase of year during 2000–2013, which was from 7.5% to 68.1% in males (P < 0.05) and from 16.2% to 66.7% in females. While the proportion of nodule size > 1.0 cm decreased during this period whether in males or in females (Fig. 2B). Of course, it was opposite to the proportion of nodule size ≤ 1.0 cm (Fig. 2C).

**BMI.** The differences of proportion of DTC were no significant among the four BMI groups in female, while the U shape was observed in male (Fig. 3). Compared to the female, in the obesity groups, the proportions of DTC in male were higher in the obesity group (P = 0.001) and lower in the normal group (P < 0.001).
TSH. The level of preoperative TSH was significantly higher in patients with DTC compared to the patients with benign (1.97 vs. 1.57 mIU/L, P < 0.001), which was similar in male (1.66 vs. 1.44 mIU/L, P = 0.001) and in female (2.08 vs. 1.62 mIU/L, P < 0.001) respectively.

The proportions of DTC in male (38.1%) and in female (31.1%) were lowest in the 0.3–1.0 MIU/L group of serum TSH (Fig. 3). There were no significant differences of serum TSH between male and female in the four groups (all P > 0.05). The proportion of DTC was highest (55.5%) in the 1.9–4.8 MIU/L group of serum TSH in female, while it was highest in the > 4.8 MIU/L group in male.

Blood types. Of all the thyroid nodules, the percentage of thyroid cancer in thyroid nodules was higher in patients with blood type AB than other blood types (Fig. 4). The similar result was observed in female and the lowest proportion was blood type B. However the proportion of thyroid cancer was dominated in blood type B and the lowest incidence in blood type A in male. But there were no significant difference in different blood type.

Multiple analysis. The results of logistic regression model showed that age, nodule number, BMI and serum TSH were the related factors for DTC in the study subjects (Table 3). Compared with normal weight group, the OR of the thin, partial fat and obesity for DTC were 1.304 (95%CI 1.064–1.598), 0.46 (95%CI 0.03–0.73) and 1.22 (95%CI 1.043–1.425) However, when male and female were analyzed separately, compared with the normal weight group, only OR of the thin was statistically significant. The OR for DTC increased along with serum TSH increasing when serum TSH < 4.8 mIU/L. Higher TSH level was related to the DTC occurrence in male or female. However, compared to the group of 0.3 ≤ TSH < 1.0 mUI/L, the patients with TSH > 0.3 mUI/L or 1.0 ≤ TSH < 1.9 mUI/L had a significant higher proportion in female. The patients with multiple nodules had
a higher proportion of DTC compared to single nodule (OR = 1.185, 95% CI 1.015–1.383, P = 0.031) while no significant differences were found in male or female.

**Pathological characteristics of DTC.** Compared with female, male had significantly higher rates of III/IV TNM Stage (12.3% vs. 18.7%, P < 0.001), lymph node metastasis (24.1% vs. 32.9%, P < 0.001) and extra thyroidal invasion (3.7% vs. 7.0%, P < 0.001) in Table 4.

**Discussion**
Thyroid cancer is the most common endocrine malignancy with the increasing new patients diagnosed worldwide. In the United States, thyroid cancer has been reported to account for about 1.0–1.5% of newly diagnosed
The tumor of thyroid has long been established to have an obvious female predominance. It has been ranked fifth in the most common cancer of female, while not in the list of 15 most common male cancers. Male patients with thyroid cancer had poor prognosis than their female counterparts. The study by Li et al. has indicated that gender was an independent predictive factor for malignant thyroid nodules, with male patients had 0.78-fold risk for development of malignant thyroid nodules. This study showed that tumor sizes of our male patients were larger than that of female patients. There were more patients of advanced thyroid cancer, lymphatic metastasis and extra-thyroid invasiveness in male patients, suggested the more malignant behaviors in male patients with thyroid cancer.

According to the investigation by Yang et al., the standardized incidence rates of thyroid cancer in urban Beijing were 11.1% in male and 12.1% in female during 1995 to 2010. The development of thyroid cancer has been suggested to associate with age and gender of the individuals. In the present study, we mainly focused on the thyroid cancer patients underwent thyroidectomy. In thyroid nodule patients underwent thyroidectomy, the

| Variables | OR   | 95% CI Lower | 95% CI Upper | P value |
|-----------|------|--------------|--------------|---------|
| Overall   |      |              |              |         |
| Gender    | 0.966| 0.823        | 1.132        | 0.666   |
| Nodule number (single) | 1.185| 1.015        | 1.383        | 0.031   |
| Age       | 0.954| 0.948        | 0.960        | <0.001  |
| Body mass index (kg/m²) |      |              |              |         |
| 18.5–24   | 1.000|              |              |         |
| <18.5     | 1.304| 1.064        | 1.598        | 0.011   |
| 24–28     | 0.462| 0.294        | 0.728        | 0.001   |
| ≥28       | 1.221| 1.043        | 1.425        | 0.013   |
| Thyroid stimulating hormone |      |              |              |         |
| <0.3      | 1.000|              |              |         |
| 0.3–1.0   | 1.730| 1.395        | 2.146        | <0.001  |
| 1.0–1.9   | 2.465| 2.000        | 3.037        | <0.001  |
| 1.9–4.8   | 2.566| 1.917        | 3.434        | <0.001  |
| ≥4.8      | 1.527| 1.122        | 2.080        | 0.007   |
| Male patients |      |              |              |         |
| Age       | 0.934| 0.922        | 0.946        | <0.001  |
| Nodule number (single) | 1.048| 0.786        | 1.397        | 0.751   |
| Body mass index (kg/m²) |      |              |              |         |
| 18.5–24   | 1.000|              |              |         |
| <18.5     | 1.632| 1.122        | 2.376        | 0.010   |
| 24–28     | 0.956| 0.183        | 5.000        | 0.958   |
| ≥28       | 1.342| 0.959        | 1.879        | 0.086   |
| Thyroid stimulating hormone |      |              |              |         |
| <0.3      | 1.755| 0.938        | 3.284        | 0.078   |
| 0.3–1.0   | 1.000|              |              |         |
| 1.0–1.9   | 1.235| 0.851        | 1.792        | 0.267   |
| 1.9–4.8   | 1.780| 1.219        | 2.599        | 0.003   |
| ≥4.8      | 2.649| 1.395        | 5.030        | 0.003   |
| Female patients |      |              |              |         |
| Age       | 0.964| 0.956        | 0.971        | <0.001  |
| Nodule number (single) | 1.208| 1.001        | 1.447        | 0.039   |
| Body mass index (kg/m²) |      |              |              |         |
| 18.5–24   | 1.000|              |              |         |
| <18.5     | 0.444| 0.275        | 0.716        | 0.001   |
| 24–28     | 1.164| 0.972        | 1.395        | 0.099   |
| ≥28       | 1.123| 0.867        | 1.454        | 0.380   |
| Thyroid stimulating hormone |      |              |              |         |
| <0.3      | 1.441| 1.002        | 2.071        | 0.049   |
| 0.3–1.0   | 1.000|              |              |         |
| 1.0–1.9   | 2.058| 1.574        | 2.691        | <0.001  |
| 1.9–4.8   | 2.824| 2.188        | 3.645        | <0.001  |
| ≥4.8      | 2.644| 1.890        | 3.699        | <0.001  |

Table 3. The related factors of thyroid malignancy by logistic regression model.
glycoconjugates may lead to modifications that related to the tumor development and spread. One study by Gong et al. in China indicated that individuals with blood type B were more likely to develop esophagus cancer and cholangiocarcinoma. Our study showed that the risk of thyroid cancer was significantly higher in blood type B patients (OR = 1.30, 95% CI = 1.02–1.66) compared with patients with other blood types.

The findings of our study showed that the prevalence of thyroid cancer was higher among male thyroid nodule patients with blood type B when compared with these with other blood types. By contrast, in the female counterpart, thyroid nodule patients with blood type AB showed higher risk for development of thyroid cancer. However, the data were not found to be statistically significant.

The incidence of thyroid cancer has been reported to be comparatively higher and occurs earlier in female patients than their male counterparts, with a male/female ratio of 1:3. However, there was no gender predilection in the onset of thyroid cancer in our study. The age of DTC diagnosis was not significantly different between male and female patients, while other clinical characteristics were found to be markedly different.

Previous meta-analysis showed that patients with multi-nodular goiters have lower risk for development of thyroid cancer than these with uninnodular goiter. Fine needle aspiration has been recommended in uninnodular goiter patients with tumor size of greater than 1 cm according to the treatment guidelines of thyroid nodule; while in patients with multi-nodular goiters, fine needle aspiration was recommended when the clinical symptom or ultrasound examination indicated malignant disease. Corroborating the results of previous study, present study showed that the incidence of DTC was obviously higher in patients with uninnodular goiter than that of multi-nodular goiter patients. Further gender-based analysis indicated that, in male, uninnodular goiter patients have a higher risk of development of DTC than their multi-nodular goiter counterparts. By contrast, no significant difference was observed in female patients with uni- or multi-nodular goiters. These results indicated that male and uninnodular goiter may be the independent risk factors for development of DTC, and patients with male gender and uninnodular goiter should be clinically managed more cautiously.

Despite the lower incidence of male thyroid cancer, the disease has been reported to be more invasive in male patients, with the higher lymphatic metastasis and poorer prognosis. Our study showed more cases of male patients with advanced DTC, and the incidence of lymphatic metastasis and extra-thyroid invasiveness were significantly higher in male DTC patients when compared with female patients. This gender-related difference may be partially explained by the younger age (<55 years) of the DTC patients recruited in this study. Previous study has indicated that, female patients with thyroid cancer diagnosed before 55 years of age had better prognosis than their male counterparts. However, no prognostic difference was observed between male and female patients when the disease was diagnosed later than 55 years old. Estrogen and estrogen receptor may play a critical role in the gender-related difference of patients younger than 55 years of age.

The present study described the gender-related difference in clinical and ultrasound characteristics, tumor staging, and aggressive behavior (lymphatic metastasis and extra-thyroid invasiveness) of the DTC patients. Factors, including diet, environment, hormone, heredity, genetic variation, and etc., may all play a role in this procedure. Our future study may focus on the potential mechanisms of this gender-related difference in thyroid cancer, and genome-wide single nucleotide polymorphism analysis may be used to identify novel susceptibility genes. Besides, in view of the more aggressive behaviors of DTC in male patients, much more attention should be focused on the timely diagnosis and treatment of these patients.

### Table 4. Clinical pathological characteristics of DTC.

| Factors                     | Male (n, %) | Female (n, %) | P Value |
|-----------------------------|-------------|---------------|---------|
| TNM Stage                   |             |               | 0.001   |
| I/II                        | 743(81.8)   | 2025(87.66)   |         |
| III/IV                      | 165(18.2)   | 285(12.34)    |         |
| Lymph node metastasis       |             |               | <0.001  |
| No                          | 609(67.1)   | 1752(75.9)    |         |
| Yes                         | 298(32.9)   | 555(24.1)     |         |
| Extra thyroidal invasion    |             |               | <0.001  |
| No                          | 842(93.0)   | 2220(96.4)    |         |
| Yes                         | 63(7.0)     | 84(3.65)      |         |

### References

1. Pellegriti, G., Frasca, F., Regalbuto, C., Squatrito, S. & Vigneri, R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013, (2013-5-7), 2013(1):965212 (2013).
2. Orosco, R. K. et al. Analysis of age and disease status as predictors of thyroid cancer-specific mortality using the Surveillance, Epidemiology, and End Results database. Thyroid 25, 125–132 (2015).
3. Sherman, S. I. Thyroid carcinoma. *Lancet* **361**, 501–511 (2003).
4. Pires, B. *et al.* Prognostic factors for early and long-term remission in pediatric differentiated thyroid cancer: the role of gender, age, clinical presentation and the newly proposed American Thyroid Association risk stratification system. *Thyroid* (2016).
5. Ito, Y. *et al.* Tumor size is the strongest predictor of microscopic lymph node metastasis and lymph node recurrence of N0 papillary thyroid carcinoma. *Endocr J* **60**, 113–117 (2013).
6. Li, T. *et al.* The derivation and validation of a prediction rule for differential diagnosis of thyroid nodules. *Chin J Intern Med* **52**, 945–950 (2013).
7. Ricarte-Filho, J. *et al.* Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension. *Thyroid* **22**, 575–584 (2012).
8. Gong, Y. *et al.* ABO blood type, diabetes and risk of gastrointestinal cancer in northern China. *World J Gastroenterol* **18**, 563–569 (2012).
9. Rai, S., Saronwala, K. C. & Singh, R. ABO blood groups in cancer of the gastro-intestinal tract. *Indian J Cancer* **9**, 97–100 (1972).
10. Risch, H. A. *et al.* ABO blood group and risk of pancreatic cancer: a study in Shanghai and meta-analysis. *Am J Epidemiol* **177**, 1326–1337 (2013).
11. Zhou, B. F. Cooperative Meta-Analysis Group of the Working Group on Obesity in China. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults--study on optimal cut-off points of body mass index and waist circumference in Chinese adults. *Biomed Environ Sci* **15**, 83–96 (2002).
12. Shi, L. *et al.* Usefulness of serum thyrotropin for risk prediction of differentiated thyroid cancers does not apply to microcarcinomas: results of 1,870 Chinese patients with thyroid nodules. *Endocr J* **59**, 973–980 (2012).
13. Cerfolios, R. J. *et al.* Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. *Chest* **130**, 1796–1802 (2006).
14. Yang, L., Sun, T. T., Yuan, Y. N. & Wang, N. Time trends and pathological characteristics of thyroid cancer in urban Beijing, 1995–2010. *Zhonghua Yu Fang Yi Xue Za Zhi* **47**, 109–112 (2013).
15. Cao, H. *et al.* Meta-analysis of total thyroidectomy for multinodular goiter. *Zhong Nan Da Xue Xue Bao Yi Xue Ban* **39**, 625–631 (2014).
16. Gharib, H. *et al.* American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules–2016 Update. *Endocr Pract* **22**, 622–639 (2016).
17. Rahbari, R., Zhang, L. & Kebebew, E. Thyroid cancer gender disparity. *Future Oncol* **6**, 1771–1779 (2010).
18. Jonklaas, J. *et al.* The impact of age and gender on papillary thyroid cancer survival. *J Clin Endocrinol Metab* **97**, E878–887 (2012).

**Acknowledgements**

This study was supported by a grant from the Medical Science and Technology Foundation of Military “Twelve-Five” Program (CWS11 J063).

**Author Contributions**

H.X.Y. conceived and designed the experiments. P.P., F.L.W. and W.T. performed the experiments. Y.K.L., W.H. and G.Q.Y. contributed reagents, materials and equipment. N.J., L.Z., J.D. and J.M.B. wrote the manuscript. J.T.D., Y.M.M. and Z.H.L. reviewed the manuscript. All authors reviewed the manuscript.

**Additional Information**

**Competing Interests:** The authors declare that they have no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017